Phenylamino isothiazole carboxamidines as MEK inhibitors

Details Phenylamino isothiazole carboxamidines as MEK inhibitors Phenylamino isothiazole carboxamidines as MEK inhibitors

2006-01-20

2008-09-30

Anderson, Rebecca L (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C544S145000, C544S298000, C544S367000, C546S145000, C546S171000, C546S209000, C546S256000, C546S271100

Reexamination Certificate

active

07429667

ABSTRACT:
The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.

REFERENCES:
patent: 5596008 (1997-01-01), Lee et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 6235764 (2001-05-01), Larson et al.
patent: 6495582 (2002-12-01), Hale et al.
patent: 6511993 (2003-01-01), Dack et al.
patent: 6548526 (2003-04-01), Larson et al.
patent: 6649640 (2003-11-01), Hale et al.
patent: 6989451 (2006-01-01), Zhang et al.
patent: 2003/0149015 (2003-08-01), Barrett et al.
patent: 2004/0029898 (2004-02-01), Boyle et al.
patent: 2004/0039037 (2004-02-01), Zhang et al.
patent: 2004/0152691 (2004-08-01), Lippa et al.
patent: 2005/0143438 (2005-06-01), Wallace et al.
patent: 2007/0238710 (2007-10-01), Yan et al.
patent: 2007/0244164 (2007-10-01), Yan et al.
patent: 2008/0058340 (2008-03-01), Maderna et al.
patent: 0 239 362 (1987-09-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 780 386 (1997-06-01), None
patent: 0 818 442 (1998-01-01), None
patent: 0 931 788 (1999-08-01), None
patent: 1 004 578 (2000-05-01), None
patent: 1 181 017 (2002-02-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 98/03516 (1998-01-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/30566 (1998-07-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/34915 (1998-08-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 99/07675 (1999-02-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/52889 (1999-10-01), None
patent: WO 99/52910 (1999-10-01), None
patent: WO 03/043985 (2003-05-01), None
Berge et al., “Pharmaceutical salts,” J. Pharm. Sci. 66(1): 1-19, 1977.
Buchwald et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,” Surgery 88(4): 507-16, 1980.
Bundgaard, H. Chapter 5: Design and application of prodrugs. A Textbook of Drug Design and Development. Krosgaard-Larsen, et al., eds., pp. 113-91, 1991.
Bundgaard, H., “Means to enhance penetration: Prodrugs as a means to improve the delivery of peptide drugs,” Advanced Drug Delivery Reviews 8: 1-38, 1992.
Fedorak et al., “A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis,” Am J Physiol 269(2 Pt 1): G210-8, 1995.
Fleisher et al., “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs,” Advanced Drug Delivery Reviews 19(2): 115-30, 1996.
Furniss et al., ed., Vogel's Textbook of Practical Organic Chemistry, 5th Ed. Suppl. (Longman Scientific and Technical Ltd, Essex, UK) pp. 809-16, 1991.
Gennaro, A., ed., Remington's Pharmaceutical Sciences, 18th Edition (Mack Publishing Company, Easton PA), pp. 62 and 1686, 1990.
Gennaro, A., ed. Remington's Pharmaceutical Sciences, 21st Edition (Mack Publishing Company, Easton PA), p. 958, 2005.
Goodman et al., eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th Edition (McGraw-Hill, New York), p. 11, 1996.
Goodson, J. Dental applications. Medical Applications of Controlled Release, vol. 2, Applications and Evaluations. Langer, et al., eds. (CRC Press, Boca Raton, FL) pp. 115-38, 1984.
Heller, A., “Electrical wiring of redox enzymes,” Acc Chem Res 23(5): 128-34, 1990.
Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed Chromatogr. 1992; 6(6): 283-286, 1992.
Langer, R., “New methods of drug delivery,” Science 249(1976): 1527-33, 1990.
Larsen, et al., “Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivative, N-sulfonylamidines, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives,” Int J Pharmaceutics 37(1-2): 87-95, 1987.
Larsen et al., “Prodrug forms for the sulfonamide group, II. Water-soluble amino acid derivatives of N-methylsulfonamides as possible prodrugs,” Int J Pharmaceutics 47(1-3): 103-10, 1988.
McLeod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterology 106(2): 405-13, 1994.
Robinson et al., “Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH group,” J Med Chem 39(1): 10-18, 1996.
Saudek et al., “A preliminary trial of the programmable implantable medication system for insulin delivery,” N Engl J Med 321(9): 574-9, 1989.
Saulnier et al., “An efficient method for the synthesis of guanidino prodrugs,” Bioorganic & Medicinal Chemistry Letters 4(16): 1985-90, 1994.
Sefton, M., “Implantable pumbs,” Crit Rev Biomed Eng 14(3): 201-40, 1987.
Sinkula et al., “Rationale for design of biologically reversible drug derivatives: prodrugs,” J Pharm Sci 64(2): 181-210, 1975.
Treat et al., “Liposome encapsulated doxorubicin: Preliminary results of phase I and phase II trials,” Liposomes in the Therapy of Infectious Diseases and Cancer. Lopez-Bernstein, et al., eds. (Alan R. Liss, New York) pp. 353-65, 1989.
Varaprasad et al., “Discovery of 3-hydroxy-4-carboxyalkylamindino-5-arylamino-isothiazoles as potent MEK1 inhibitors,” Bioorg Med Chem Let 16(15):3975-3980, 2006.
Widder et al., ed., Methods in Enzymology (Academic Press, New York) vol. 112, pp. 309-396, 1985.
Vernier et al., “Inhibitors of MEK,” U.S. Appl. No. 12/016,897 filed Jan. 18, 2008.

Affiliated with

Also associated with

Rating

Phenylamino isothiazole carboxamidines as MEK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phenylamino isothiazole carboxamidines as MEK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylamino isothiazole carboxamidines as MEK inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3986463